1. Home
  2. HUIZ vs TPST Comparison

HUIZ vs TPST Comparison

Compare HUIZ & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huize Holding Limited

HUIZ

Huize Holding Limited

SELL

Current Price

$2.10

Market Cap

12.6M

Sector

Finance

ML Signal

SELL

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$0.29

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUIZ
TPST
Founded
2006
2011
Country
China
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6M
13.7M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
HUIZ
TPST
Price
$2.10
$0.29
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.4K
★ 182.0K
Earning Date
08-20-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $295,000.00
Revenue This Year
$6.27
N/A
Revenue Next Year
$11.13
N/A
P/E Ratio
$7.81
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.04
$0.29
52 Week High
$3.83
$4.22

Technical Indicators

Market Signals
Indicator
HUIZ
TPST
Relative Strength Index (RSI) 49.77 20.25
Support Level $1.52 N/A
Resistance Level $2.16 $0.56
Average True Range (ATR) 0.17 0.05
MACD -0.04 0.00
Stochastic Oscillator 27.66 4.46

Price Performance

Historical Comparison
HUIZ
TPST

About HUIZ Huize Holding Limited

Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners. Geographically, the company is concentrated in PRC Mainland, Hong Kong and others segments.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: